Core Insights - ACA Pharma has entered into an exclusive distribution agreement with Eagle Pharmaceuticals to commercialize Ryanodex® and Barhemsys® in Hong Kong, Macau, Singapore, and Greater China [2][5][6] Product Overview - Ryanodex® (dantrolene sodium for injection) is indicated for the treatment and prevention of malignant hyperthermia, while Barhemsys® (amisulpride injection) is used for the prevention and treatment of postoperative nausea and vomiting (PONV) [3][9] - Both products have established use in the U.S. and are positioned for rapid market entry in Asia [3][5] Regulatory Progress - Ryanodex has completed fast-track registration in Macau, while Barhemsys is still undergoing registration processes in Macau, Hong Kong, and Singapore [4][5] - ACA Pharma is also pursuing national registration in China and aims to include both products on Hainan's Urgently Needed Clinical Medicines List for accelerated adoption [4][5] Market Positioning - Despite competition from local generics in China, imported originator medicines like Ryanodex and Barhemsys maintain a competitive edge in hospitals [5] - ACA Pharma plans to expand the distribution of both products into Latin America, Asia, Europe, and other regions through global alliances and fast-track pathways [5][6] Strategic Vision - The agreement allows ACA Pharma to provide healthcare professionals and patients with access to critical hospital medicines quickly, addressing urgent unmet needs across multiple regions [6] - ACA Pharma's established fast-track regulatory pathways enable patient access in as little as 30–90 days, targeting leading hospitals in the Greater Bay Area and beyond [7]